Last $9.55 USD
Change Today -0.09 / -0.93%
Volume 6.4K
ORMP On Other Exchanges
As of 9:41 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

oramed pharmaceuticals inc (ORMP) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - $31.73
52 Week Low
09/30/13 - $6.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

oramed pharmaceuticals inc (ORMP) Related Bloomberg News

View More Bloomberg News

oramed pharmaceuticals inc (ORMP) Related Businessweek News

No Related Businessweek News Found

oramed pharmaceuticals inc (ORMP) Details

Oramed Pharmaceuticals, Inc., a development stage pharmaceutical company, is engaged in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company’s product portfolio includes ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.

oramed pharmaceuticals inc (ORMP) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $259.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $98.4K
Chief Operating Officer and Vice President of...
Total Annual Compensation: $48.4K
Chief Medical & Technology Officer and Direct...
Total Annual Compensation: $188.4K
Compensation as of Fiscal Year 2013.

oramed pharmaceuticals inc (ORMP) Key Developments

Oramed Pharmaceuticals Inc. Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes

Oramed Pharmaceuticals Inc. reported that the last patient has completed treatment in its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsule, to treat type 1 diabetes, and top-line data is expected to be reported in the fourth quarter of 2014. The trial was conducted in the United States under a Food and Drug Administration Investigational New Drug protocol. The prospective, randomized, double-blind, placebo controlled study in patients with established type 1 diabetes is evaluating the safety and impact of ORMD-0801 on the exogenous insulin requirements in 24 type 1 diabetics patients.

Oramed Pharmaceuticals Approves Amendment to Certificate of Incorporation

Oramed Pharmaceuticals Inc. announced that at the annual meeting of the stockholders held on July 23, 2014, the company approved amendment to Company's Certificate of Incorporation to increase the Company's authorized common stock from 16,666,667 shares to 30,000,000 shares.

Oramed Pharmaceuticals Inc. Proposes Amendment to Certificate of Incorporation

Oramed Pharmaceuticals Inc. proposed amendment to the company's Certificate of Incorporation to increase the company's authorized common stock from 16,666,667 shares to 30,000,000 shares at its AGM to be held on July 23, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORMP:US $9.55 USD -0.09

ORMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ORMP.
View Industry Companies

Industry Analysis


Industry Average

Valuation ORMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORAMED PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at